



## Addressing the Opioid Epidemic in Primary Care

**Jan Losby, PhD**, Team Lead for the Prescription Drug Overdose Health Systems Team

**Joann Yoon Kang, JD**, Team Lead for Policy and Partnerships



Division of Unintentional Injury Prevention  
Centers for Disease Control and Prevention

American Medical Student Association

October 5, 2016

# CDC PRIORITIES: Unintentional Injury Prevention



Motor Vehicle Safety



Prescription Drug Overdose




Older Adult Falls



Traumatic Brain Injury

# Rise in Rx overdose deaths since 2000 and recent increase in heroin & fentanyl deaths



# Pillars of CDC Activity


- **Improve data** quality and track trends
- **Strengthen state efforts** by scaling up effective public health interventions
- **Supply healthcare providers with resources** to improve patient safety



# Chronic Pain and Prescription Opioids

- 11% of Americans experience daily (chronic) pain.
- Opioids frequently prescribed for chronic pain.
- Primary care providers commonly treat chronic, non-cancer pain.
  - Account for ~50% of opioid pain medications dispensed.
  - Report concern about opioids and insufficient training.





The amount  
of opioids prescribed has  
**QUADRUPLED**  
from 1999-2014,





but the pain that  
Americans report remains  
**UNCHANGED**



Since 1999, there  
have been more than

**165,000**

deaths from overdose related to  
prescription opioids.



## CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016



Continuing Education Examination available at <http://www.cdc.gov/mmwr/cme/conted.html>.




U.S. Department of Health and Human Services  
Centers for Disease Control and Prevention


- **Primary care**
- **Outpatient settings**
- **Outside of active cancer, palliative, and end of life**
- **Patients > 18 Years with chronic pain**



# Why Primary Care Providers?




# Guideline development process



# THE EVIDENCE

- 1 Lack of evidence that opioids control pain effectively long term.
- 2 Risk of serious harm increases with opioid dose.
- 3 Up to a quarter of patients receiving opioids long-term in a primary care setting struggles with addiction.

## WHAT CAN PROVIDERS DO?



- 1 First, **do no harm**. Opioids are not first-line or routine therapy for chronic pain.
- 2 When opioids are used, prescribe the lowest effective dosage.
- 3 Exercise caution when prescribing opioids and monitor all patients closely.

# Organization of recommendations

- **The 12 recommendations are grouped into three conceptual areas:**
  - Determining when to initiate or continue opioids for chronic pain
  - Opioid selection, dosage, duration, follow-up, and discontinuation
  - Assessing risk and addressing harms of opioid use

# Determining when to initiate or continue opioids for chronic pain


- 1 Opioids are not first-line or routine therapy for chronic pain
- 2 Establish and measure goals for pain and function
- 3 Discuss benefits and risks and availability of nonopioid therapies with patient

# Opioid selection, dosage, duration, follow-up, and discontinuation


- 4 Use short-acting opioids when starting
- 5 Start with the lowest effective dose, carefully reassess before increasing, and avoid or justify high dosages
- 6 When opioids are needed for acute pain, prescribe no more than needed
- 7 Follow up and re-evaluate risk of harm; reduce dose or taper and discontinue if needed

# Assessing risk and addressing harms of opioid use

- 8 Evaluate risk factors for opioid-related harms
- 9 Check PDMP for high dosages and prescriptions from other providers
- 10 Use urine drug testing to identify prescribed substances and undisclosed use
- 11 Avoid concurrent benzodiazepines and opioids
- 12 Arrange treatment for opioid use disorder if needed



## Implementation Activities







# CDC Guideline Implementation



Translation and Communication



Clinical Training




Health System Implementation



Insurer/Pharmacy Benefit Manager  
Implementation


# Educational Resources



## Patient materials


- Graphics and messages
- Fact sheets
- Posters
- Podcasts
- Infographics

# Fact Sheets



- New Opioid Prescribing Guideline
- Assessing Benefits and Harms of Opioids
- Prescription Drug Monitoring Programs
- Calculating Total Daily Dose of Opioids
- Pregnancy and Opioid Pain Medications

# Clinical Tools



## Provider materials

- Checklist
- Pocket Guides
  - Tapering
  - Overview
- Fact sheets
  - New Opioid Prescribing Guideline
  - Assessing Benefits and Harms of Opioid Therapy
  - Prescription Drug Monitoring Programs
  - Calculating Total Daily Dose of Opioids for Safer Prescribing



# EMPOWERING PROVIDERS.

[www.cdc.gov](http://www.cdc.gov)

GUIDELINE FOR PRESCRIBING  
OPIOIDS FOR CHRONIC PAIN

# Checklist for prescribing opioids for chronic pain

## Checklist for prescribing opioids for chronic pain

For primary care providers treating adults (18+) with chronic pain  $\geq 3$  months, excluding cancer, palliative, and end-of-life care

### CHECKLIST

#### When CONSIDERING long-term opioid therapy

- ☐ Set realistic goals for pain and function based on diagnosis (eg, walk around the block).
- ☐ Check that non-opioid therapies tried and optimized.
- ☐ Discuss benefits and risks (eg, addiction, overdose) with patient.
- ☐ Evaluate risk of harm or misuse.
  - Discuss risk factors with patient.
  - Check prescription drug monitoring program (PDMP) data.
  - Check urine drug screen.
- ☐ Set criteria for stopping or continuing opioids.
- ☐ Assess baseline pain and function (eg, PEG scale).
- ☐ Schedule initial reassessment within 1–4 weeks.
- ☐ Prescribe short-acting opioids using lowest dosage on product labeling; match duration to scheduled reassessment.

#### If RENEWING without patient visit

- ☐ Check that return visit is scheduled  $\leq 3$  months from last visit.

#### When REASSESSING at return visit

*Continue opioids only after confirming clinically meaningful improvements in pain and function without significant risks or harm.*

- ☐ Assess pain and function (eg, PEG); compare results to baseline.
- ☐ Evaluate risk of harm or misuse:
  - Observe patient for signs of over-sedation or overdose risk.
  - If yes: Taper dose.
  - Check PDMP.
  - Check for opioid use disorder if indicated (eg, difficulty controlling use).
  - If yes: Refer for treatment.
- ☐ Check that non-opioid therapies optimized.
- ☐ Determine whether to continue, adjust, taper, or stop opioids.
- ☐ Calculate opioid dosage morphine milligram equivalent (MME).
  - If  $\geq 50$  MME/day total ( $\geq 50$  mg hydrocodone;  $\geq 33$  mg oxycodone), increase frequency of follow-up; consider offering naloxone.
  - Avoid  $\geq 90$  MME/day total ( $\geq 90$  mg hydrocodone;  $\geq 60$  mg oxycodone), or carefully justify; consider specialist referral.
- ☐ Schedule reassessment at regular intervals ( $\leq 3$  months).

### REFERENCE

#### EVIDENCE ABOUT OPIOID THERAPY

- Benefits of long-term opioid therapy for chronic pain not well supported by evidence.
- Short-term benefits small to moderate for pain; inconsistent for function.
- Insufficient evidence for long-term benefits in low back pain, headache, and fibromyalgia.

#### NON-OPIOID THERAPIES

- Use alone or combined with opioids, as indicated:
  - Non-opioid medications (eg, NSAIDs, TCAs, SNRIs, anti-convulsants).
  - Physical treatments (eg, exercise therapy, weight loss).
  - Behavioral treatment (eg, CBT).
  - Procedures (eg, intra-articular corticosteroids).

#### EVALUATING RISK OF HARM OR MISUSE

Known risk factors include:

- Illegal drug use; prescription drug use for nonmedical reasons.
- History of substance use disorder or overdose.
- Mental health conditions (eg, depression, anxiety).
- Sleep-disordered breathing.
- Concurrent benzodiazepine use.

**Urine drug testing.** Check to confirm presence of prescribed substances and for undisclosed prescription drug or illicit substance use.

**Prescription drug monitoring program (PDMP):** Check for opioids or benzodiazepines from other sources.

#### ASSESSING PAIN & FUNCTION USING PEG SCALE

PEG score = average 3 in individual question scores (0 = no improvement from baseline is clinically meaningful)

Q1: What number from 0–10 best describes your pain in the past week?

0 = "no pain"; 10 = "worst you can imagine"

Q2: What number from 0–10 describes how, during the past week, pain has interfered with your enjoyment of life?

0 = "not at all"; 10 = "complete interference"

Q3: What number from 0–10 describes how, during the past week, pain has interfered with your general activity?

0 = "not at all"; 10 = "complete interference"



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

TO LEARN MORE  
[www.cdc.gov/opa/pressroom/pressroom/030116.html](http://www.cdc.gov/opa/pressroom/pressroom/030116.html)

March 2016

# Training Resources: Webinars

## COCA webinar series

1. Overview
2. Nonopioid Treatments for Chronic Pain
3. Assessing Benefits and Harms of Opioid Therapy
4. Dosing and Titration of Opioids



**Additional webinars coming soon!**

# Training Resources: Online Course



## eLearning

- Web-based training
- Modules that can be completed in 30 minutes or less
- Learner-directed content
- Scenario-based interactions
- Mini-lessons on implementing the guideline
- Short videos



## Coming Soon

- Mobile “app” with MME calculator
- Videos
- Brochures and pocket guides
- Online training for providers
- Additional materials, such as matte articles, blogs, infographics




# Health Systems

- Quality Improvement (QI) Initiative
  - Create QI measures
  - Create QI implementation guide
  - Launch & support Opioid QI Collaborative
- Clinical Decision Supports
  - Create sharable EHR code/artifacts
  - Clinical sites to implement guideline & track outcomes

## Health Systems (continued)

- Coordinated Care Plan
  - Create the *Chronic Pain Care Involving Opioids: A Coordinated Care Plan for Safer Practice*
  - Rigorous evaluation (9 clinical intervention sites & 9 clinical comparison sites)
  - Broad dissemination following evaluation period
- State-led efforts through CDC-funded states
  - EHR and PDMP (prescription drug monitoring program) integration
  - Guideline uptake

# Insurer Interventions



# Insurers

- CMS (Medicaid and Medicare)
  - Metric harmonization (MME threshold)
  - Checking PDMP
- Commercial payers
- Pharmacy Benefit Managers
- State-led efforts through CDC-funded states:
  - Medicaid
  - Workers' Compensation
  - National Council for Behavioral Health

# Resources

CDC Opioid Overdose Prevention Website  
[www.cdc.gov/drugoverdose](http://www.cdc.gov/drugoverdose)

CDC Media Toolkit  
[CDC Newsroom](#)

HHS Prescription Drug & Heroin Overdose Epidemic  
[www.hhs.gov/opioids](http://www.hhs.gov/opioids)

Turn the Tide (U.S. Surgeon General's website)  
<http://turnthetiderx.org/#>

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

